If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Early life and education == Lucy Letby was born on 4 January 1990 in Hereford, the only child of a furniture salesman and an accounts clerk. She attended St. James' Church of England primary school, Aylestone School and Hereford Sixth Form College. According to a friend interviewed by the BBC, she had long expressed an interest in neonatal nursing. Letby studied child nursing at the University of Chester, completing clinical placements at Liverpool Women's Hospital and the Countess of Chester Hospital. During her final year she failed an assessed placement but passed a subsequent retrieval placement after requesting a different assessor. One of her assessors later told the 2024 statutory inquiry that she had considered Letby inexperienced and lacking confidence in some clinical areas. Letby graduated with a Bachelor of Science in Nursing with a speciality in child nursing in September 2011 and completed a further placement at Liverpool Women's Hospital the following year.
=== Judges' Costumes === Episode 1: Carla Hall as a neuroscientist with an exposed brain, Stephanie Boswell as a chemist mutated by a chemical spill, and Zac Young as a beaker of green slime Episode 2: Carla Hall as a victim of an exploding stand mixer, Stephanie Boswell as a victim of killer macarons, and Zac Young as a victim of a sprinkles allergy Episode 3: Carla Hall as a creepy psychedelic bunny, Stephanie Boswell as a cutesy bunny, and Zac Young as a monstrous bunny Episode 4: Carla Hall as a skeleton lady, Stephanie Boswell as a mummy influencer, and Zac Young as Mummy Dearest Episode 5: Carla Hall as a house's front door, Stephanie Boswell as a tornado, and Zac Young as a cow Episode 6: Carla Hall as a headless demon, Stephanie Boswell as the nosey neighbor from Hades, and Zac Young as a goat demon Episode 7: Carla Hall as a were-chicken, Stephanie Boswell as a reanimated lady, and Zac Young as a vampire agent
Delayed puberty (and dysmenorrhoea or amenorrhoea in women) in young people Severe kidney damage: high blood sugar can overwork the kidneys, eventually leading to kidney failure and the need for a kidney transplant Severe neuropathy (nerve damage to hands and feet) Extreme fatigue Edema (during blood sugars controlled phases) Heart problems Retinal damage and subsequent vision problems High cholesterol (hypercholesterolaemia) Osteoporosis Death
Sources: en.wikipedia.org
This basic structure was not touched by the Abbott, Turnbull and Morrison governments, although wages and standards continued to decline through lack of enforcement, growing casualization, and hostile judicial decisions. With the Albanese government, a series of reforms, such as the Fair Work Legislation Amendment (Closing Loopholes) Bill, aimed to raise protection, since Australian labour rights remained significantly below European and wealthier countries' standards. This includes the lack of a restored system for sectoral collective bargaining, weak protection for collective action, and absence of rights for workers to elect directors on boards of enterprises, outside isolated examples in universities or the Australian Broadcasting Corporation, 25 per cent of people on "casual" contracts, and stagnating real wages.
=== P53 and p73 === p53 and p73 are tumor suppressor proteins and their degradation is tightly regulated by ubiquitination. Recently it was shown that their degradation can also occur via an ubiquitin-independent process; NQO1 blocks p53 and p73 degradation in the presence of NADH and protects them from 20S proteasomal degradation. This protein-protein interaction between p53 and NQO1 was non-catalytic.
Thus, the amount of material left is 2−1 = 1/2 raised to the (whole or fractional) number of half-lives that have passed. Thus, after 3 half-lives there will be 1/23 = 1/8 of the original material left. Therefore, the mean lifetime
Sources: en.wikipedia.org
=== Abnormal folate metabolism === Several lines of evidence indicate abnormalities of folate metabolism in ASD. These abnormalities can lead to a decrease in 5-methyltetrahydrofolate production, alter the production of folate metabolites and reduce folate transport across the blood-brain barrier and in neurons. The most significant abnormalities of folate metabolism associated with ASD may be autoantibodies to the alpha folate receptor (FRα). These autoantibodies have been associated with cerebral folate deficiency. Autoantibodies can bind to FRα and greatly impair its function. In 2013, one study reported that 60% and 44% of 93 children with ASD were positive for FRα-blocking and binding autoantibodies, respectively. This high rate of anti-FRα autoantibody positivity was confirmed by Ramaekers et al. who compared 75 children with ASD to 30 non-autistic "controls". These controls were children who had a developmental delay, but did not have ASD. FRα-blocking autoantibodies were positive in 47% of children with ASD, but only in 3% of children without ASD. The authors of this study (RE Frye, JM Sequeira, EV Quadros, SJ James and DA Rossignol) have contributed to other such studies on FRα autoantibodies with similar results, however are considered to have a conflict of interest by the publishers. Many children with ASD and cerebral folate deficiency have marked improvements in their clinical status when taking folinic acid.
In the morning, Trump departed the White House and boarded Air Force One. In the evening, Air Force One made a refueling stop at Anchorage. Nvidia CEO Jensen Huang, who had not been invited initially, boarded to join the delegation.
=== Trace gas analysis === One of the first papers reporting the use of the flowing afterglow studied ion-molecule reactions pertinent to the Martian atmosphere. This flowing afterglow technique replaced the then standard stationary afterglow when the movable Langmuir probe was introduced. The flowing afterglow has many attractive aspects: well-understood laminar behavior, viscous gas flow, a large density of carrier gas which allows the study of thermalized reactions, and the capability to make new reactant ions in situ. The ambipolar plasma is sampled using a nosecone and detected using conventional quadrupole or tandem mass spectrometry, depending on the application. One of the drawbacks of the flowing afterglow technique is the possibility of generating multiple reactant ions. This problem is circumvented by implementing the selected ion flow tube (SIFT). The flowing afterglow technique can be used to identify and quantify the volatile organic compounds (VOCs) of a sample as long as the fundamental ion chemistry is known. The commonly used ions are H3O+, O2+*, and NO+. All ions have drawbacks and advantages. Strategies that have been employed to identify the VOCs include using gas chromatography coupled with flowing afterglow and using a complement of reagent ions. Also in addition to being able to detect volatile organic compounds, the flowing afterglow technique has also been used to study chronic kidney disease.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.